High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma

JAMA Oncol. 2023 May 1;9(5):725. doi: 10.1001/jamaoncol.2023.0108.

Authors

Yasuyuki Shigematsu¹, Kentaro Inamura²

Affiliations

¹ The Cancer Institute Hospital, Department of Pathology, Japanese Foundation for Cancer Research, Tokyo, Japan.
² The Cancer Institute, Division of Pathology, Japanese Foundation for Cancer Research, Tokyo, Japan.

PMID: 36928513
DOI: 10.1001/jamaoncol.2023.0108

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Bevacizumab
Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy
Patients

Substances

atezolizumab
Antibodies, Monoclonal, Humanized
Bevacizumab